You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Zydus Cadila files investigational new drug application for coronavirus

Drug firm Zydus Cadila said it has filed the investigational new drug application for ZYIL1, positioned for management of critically ill Covid-19 patients

Zydus Cadila | Coronavirus Vaccine | Coronavirus Tests

Press Trust of India  |  New Delhi 

Photo: Bloomberg
Representative photo of a vaccine

Drug firm on Tuesday said it has filed the investigational new drug (IND) application for ZYIL1, positioned for management of critically ill COVID-19 patients.

"Following up on its initiatives to fight COVID-19 with diagnostics, vaccines and therapeutics, the company is now focussing on cutting edge research to bring targeted therapies... it has filed the IND application of ZYIL1, a novel oral small molecule," the company said in a regulatory filing.

said ZYIL1 will bridge a critical unmet healthcare need in several inflammatory diseases including the current pandemic of COVID-19 and address complications caused by chronic and uncontrolled inflammation.

The company said it has completed all IND enabling preclinical studies and has filed the IND application to advance this drug candidate towards the clinic.

said ZYIL1, has demonstrated promising efficacy in a number of validated pre-clinical models of Inflammatory Bowel Disease (IBD), Multiple Sclerosis (MS), Sepsis and acute lung injury models of Acute Respiratory Distress Syndrome (ARDS).

Shares of Cadila Healthcare were trading 7.88 per cent higher at Rs 442.45 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 03 2020. 13:14 IST